HRP20030677B1 - Postupci primjene analoga epotilona u liječenju karcinoma - Google Patents

Postupci primjene analoga epotilona u liječenju karcinoma

Info

Publication number
HRP20030677B1
HRP20030677B1 HR20030677A HRP20030677A HRP20030677B1 HR P20030677 B1 HRP20030677 B1 HR P20030677B1 HR 20030677 A HR20030677 A HR 20030677A HR P20030677 A HRP20030677 A HR P20030677A HR P20030677 B1 HRP20030677 B1 HR P20030677B1
Authority
HR
Croatia
Prior art keywords
milliliters
hours
analogs
epotilon
procedures
Prior art date
Application number
HR20030677A
Other languages
English (en)
Croatian (hr)
Inventor
Bandyopadhyay Rebanta
M. Malloy Timothy
Panaggio Andrea
Srinivas Raghavan Krishnaswamy
Amilal Varia Sailesh
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20030677A2 publication Critical patent/HRP20030677A2/xx
Publication of HRP20030677B1 publication Critical patent/HRP20030677B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20030677A 2001-01-25 2002-01-22 Postupci primjene analoga epotilona u liječenju karcinoma HRP20030677B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000601P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (2)

Publication Number Publication Date
HRP20030677A2 HRP20030677A2 (en) 2004-08-31
HRP20030677B1 true HRP20030677B1 (hr) 2011-10-31

Family

ID=26950348

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030677A HRP20030677B1 (hr) 2001-01-25 2002-01-22 Postupci primjene analoga epotilona u liječenju karcinoma

Country Status (10)

Country Link
JP (1) JP4633331B2 (enExample)
AU (1) AU2002245296B2 (enExample)
CA (1) CA2434526C (enExample)
HR (1) HRP20030677B1 (enExample)
IL (1) IL156578A0 (enExample)
MX (1) MXPA03006412A (enExample)
NO (1) NO335119B1 (enExample)
PL (1) PL207720B1 (enExample)
RU (1) RU2292202C2 (enExample)
WO (1) WO2002058700A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2008200555C1 (en) * 2003-03-14 2011-12-15 Novartis Ag Treatment of proliferative diseases with epothilone derivatives and radiation
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
AU2008260070B9 (en) * 2007-06-01 2012-01-19 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
WO2009089138A1 (en) * 2008-01-04 2009-07-16 Bristol-Myers Squibb Company Oral administration of ixabepilone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO1999043320A1 (en) * 1998-02-25 1999-09-02 Novartis Ag Use of epothilones for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
WO1999004330A1 (en) * 1997-07-18 1999-01-28 Hewlett-Packard Company Format for passing information between devices
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
NZ506389A (en) * 1998-02-05 2003-07-25 Novartis Ag Pharmaceutical compositions containing epothilone which can be optionally lyophilised
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
RU2242229C2 (ru) * 1999-01-19 2004-12-20 Новартис Аг Применение эпотилонов для лечения рака
CZ20012951A3 (cs) * 1999-02-18 2001-11-14 Schering Aktiengesellschaft 16-Halogensubstituované deriváty epothilonu, způsoby jejich výroby a jejich farmaceutické pouľití
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO1999043320A1 (en) * 1998-02-25 1999-09-02 Novartis Ag Use of epothilones for the treatment of cancer

Also Published As

Publication number Publication date
RU2003126170A (ru) 2005-02-27
MXPA03006412A (es) 2003-10-15
NO335119B1 (no) 2014-09-22
CA2434526C (en) 2011-11-01
IL156578A0 (en) 2004-01-04
PL207720B1 (pl) 2011-01-31
HRP20030677A2 (en) 2004-08-31
CA2434526A1 (en) 2002-08-01
NO20033341L (no) 2003-09-04
AU2002245296B2 (en) 2006-12-21
JP2005503323A (ja) 2005-02-03
WO2002058700A1 (en) 2002-08-01
RU2292202C2 (ru) 2007-01-27
PL373727A1 (en) 2005-09-05
JP4633331B2 (ja) 2011-02-16
NO20033341D0 (no) 2003-07-24

Similar Documents

Publication Publication Date Title
HRP20030677B1 (hr) Postupci primjene analoga epotilona u liječenju karcinoma
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
ES2121760T3 (es) Compuesto de pirazolopiridina y procedimiento para su preparacion.
HRP20050830A2 (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
AR063555A1 (es) Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos
NO20055057L (no) Farmasoytiske blandinger for hepatitt C virale-priteaseinhibitorer
AR005053A1 (es) Compuestos de difenilhexano, un procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos, y procedmientos para la manufactura de medicamentos para inhibir la infeccion de hiv
EA200400991A1 (ru) Фармацевтические композиции, содержащие ингибиторы протеазы вируса гепатита c
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
BR0113496A (pt) Composto ou um sal farmaceuticamente aceitável ou ester hidrolisável in vivo deste, uso destes, método para produzir um efeito inibidor do ciclo celular (anti-proliferação celular) em um animal de sangue quente, e, composição farmacêutica
NO923948L (no) Tiofensulfonamider som kan anvendes som karbonsyre-anhydraseinhibitorer
YU234690A (sh) Supstituisani 4-fenil-4-piperidinkarboksamidi i postupak za njihovo dobijanje
ZA202408030B (en) Tricyclic heterocyclic derivatives, compositions and uses thereof
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
NO20013402L (no) Fremgangsmåter for behandling av ovarialcancer, poly(fosfoester)preparater, og bionedbrytbare gjenstander for detsamme
MEP56908A (en) Reconstitutable parenteral composition containing a cox-2 inhibitor
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
BRPI0513858A (pt) compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa
AR062399A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
BR0315620A (pt) Derivados de n-benzodioxolil, n-benzodioxanil e n-benzodioxepinil arilcarboxamida, e composições farmacêuticas compreendendo os mesmos
YU6396A (sh) Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160111

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20170122